Free Rx drugs in Wales despite ABPI opposition

26 February 2007

National Health Service prescription charges, a patient payment on each item regardless of quantity, are to be abolished in the principality of Wales from April this year. The move, which contrasts with a L6.65 ($12.95) fee in the rest of the UK, follows years of price freezes and a gradual reduction in the charge in Wales since 1998.

Health Minister for Wales, Brian Gibbons, explained that "the main reason for providing free prescriptions was to ensure people are not put off getting medication they need due to cost."

The Association of the British Pharmaceutical Industry's Welsh division (ABPI Cymru Wales) has expressed opposition to the proposal, arguing that it could lead to overconsumption, uncontrollable increase in demand and waste as drugs are overstocked. Richard Greville, the ABPI Wales' spokesman, said: "our concern is that a further squeeze on the medicines budget may reduce access to the range of treatments, especially in innovative medicines available to patients in Wales."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight